Octreotide acetate-steroid combination therapy for malignant gastrointestinal obstruction.
AIM
The Aim of this study was to investigate improvements in symptoms caused by gastrointestinal obstruction following administration of octreotide acetate (Sandostatin®) injection through steroid and opioid administration.


PATIENTS AND METHODS
Patients (n=37) hospitalized with malignant gastrointestinal obstruction were enrolled in the present study. Twenty seven of them were investigated for gastrointestinal symptoms using the Japanese version of the Support Team Assessment Schedule (STAS-J).


RESULTS
Octreotide acetate was administered intravenously to all 27 patients. Out of them, 17 showed a marked response, four a good response, and six no response. The overall response rate was 77.8%. Octreotide acetate with a steroid was administered to 19 patients; 13 showed a marked response, four a good response, and two no response at all. Multiple logistic regression analysis showed that that steroid administration improved the efficacy of octreotide acetate after adjusting for infusion dose (p=0.03).


CONCLUSION
Intravenous administration of octreotide acetate with steroid can effectively improve gastrointestinal symptoms due to malignant gastrointestinal obstruction without adverse events.
['Murakami|Haruaki|H|', 'Matsumoto|Hideo|H|', 'Nakamura|Masafumi|M|', 'Hirai|Toshihiro|T|', 'Yamaguchi|Yoshiyuki|Y|']
D000305:Adrenal Cortex Hormones D000368:Aged D018931:Antineoplastic Agents, Hormonal D005260:Female D005770:Gastrointestinal Neoplasms D006801:Humans D008297:Male D008875:Middle Aged D015282:Octreotide D012189:Retrospective Studies
Octreotide steroids intestinal obstruction palliative care